(Reuters) -AstraZeneca said on Friday it will invest $2 billion to expand its manufacturing footprint in Maryland as part of its previously announced $50 billion plan to expand manufacturing and research capabilities in the U.S. by 2030.
Global pharmaceutical companies have been ramping up investments in the United States to expand production capacity, following President Donald Trump's call for the industry to make more medicines domestically instead of importing active ingredients or finished products.
The Anglo-Swedish drugmaker's $2 billion investment will help expand its biologics manufacturing facility in Frederick and construct a new state-of-the-art facility in Gaithersburg for the development and clinical supply of drugs to be used in trials.
This investment marks the fourth in AstraZeneca's larger expansion plan, and will support 2,600 jobs across the two sites in Maryland, including the creation of 300 highly skilled jobs.
CEO Pascal Soriot has looked to balance Trump's demands on the sector with a full listing of its shares on the New York Stock Exchange, as well as a deal to lower drug prices for millions of Americans.
AstraZeneca's Frederick facility currently produces biologics, a class of medications that come from living organisms and include a wide range of products such as vaccines and other therapies. These are used across AstraZeneca's portfolio of cancer, autoimmune, respiratory and rare disease treatments.
The planned expansion will nearly double commercial manufacturing capacity, allowing increased supply of existing medicines and, for the first time, production across the company's rare disease portfolio, AstraZeneca said, adding that it will create 200 highly skilled jobs and 900 construction roles.
Its new clinical manufacturing facility in Gaithersburg, which will be fully operational by 2029, will create an additional 100 jobs, retain 400 roles and support a further 1,000 construction-related jobs.
The drugmaker's previous announcements included a new cell therapy manufacturing facility in Rockville, Maryland, a new drug substance manufacturing facility in Virginia and the expansion of its existing manufacturing facility in Coppell, Texas.
(Reporting by Sriparna Roy in Bengaluru; Editing by Alan Barona)
latest_posts
- 1
Vote in favor of your Favored kind of footwear - 2See the famous winged horse Pegasus fly in the autumn night sky
- 3Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
- 4Influencers are selling a delusional fantasy of being postpartum. Why is it so easy to believe?
- 5They grew up with 'almond moms.' Now, they dread going home for the holidays.
- Scientists dove hundreds of feet into the ocean and found creatures no human has ever seen. Our trash beat us there
- Jill Hennessy was a '90s TV staple. Now she's in her fearless era.
- 7 Peculiar Ways Of starting Your Imagination: Motivation Has Never Been This Good times
- Figure out how to Separate Among Fledgling and Master Fender bender Legal counselors
- Bahrain cracks down on dissent as war grinds on
- Find the Historical backdrop of Common liberties: Advancing Equity and Equity Around the world
- Artemis II astronauts will see parts of the moon no human has before. Here’s how
- Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
- Rubble, mud and hair: How to rebuild a home in Gaza
